media – Page 2 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

Recyclable living battery achieves precise blood pressure regulation. Shenzhen team develops “coin-sized” biological battery

Recently, Zhong Chao’s team from the National Key Laboratory of Quantitative Synthetic Biology of the Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences (hereinafter referred to as “Shenzhen Advanced Institute”), Liu Zhiyuan’s team from the Neuroengineering Center of the Shenzhen Institute of Advanced Technology, and Wang Renheng’s team from Shenzhen University published their latest research results in Advanced Materials. They used 3D printing living hydrogel technology to successfully develop a micro-portable microbial fuel cell with a diameter of only 20 mm, innovatively integrated a bioelectric stimulation device, and achieved precise regulation of electrophysiology and blood pressure by stimulating neurons, which has great application potential in disease treatment. This research has promoted the development of portable biological devices and expanded the research frontier of living energy materials. Interdisciplinary development of biobatteries that can be recycled In this study, the research team developed an innovative 3D printed living hydrogel material based ...
- Source: drugdu
- 68
- April 8, 2025
Yingen Biotech starts IPO today and is expected to be listed on April 15

Yingen Biotech plans to be officially listed on the Hong Kong Stock Exchange on April 15, and has received support from a lineup of luxurious cornerstone investors including BioNTech. Yingen Biotech was founded in 2019 and focuses on the research and development of antibody-drug conjugates (ADCs) to treat cancer and autoimmune diseases. The company has two core products: DB-1303/BNT323 is an ADC candidate targeting HER2 for the treatment of endometrial cancer and breast cancer. DB-1311/BNT324 is an ADC candidate targeting B7-H3 for the treatment of small cell lung cancer, castration-resistant prostate cancer, esophageal squamous cell carcinoma, and head and neck squamous cell carcinoma. In addition to its core products, Yingen Bio also has five other ADC drugs in clinical stage, namely DB-1310, DB-1305/BNT325, DB-1312/BGC9074, DB-1419 and DB-2304, with a wide range of indications; two bispecific ADCs (BsADCs): DB-1418/AVZO-1418 and DB-1421, which are expected to enter the clinical stage from 2025 ...
- Source: drugdu
- 69
- April 8, 2025
China’s biomanufacturing begins to use rice to make blood

“Rice makes blood”, a concept that sounds “fairy tale”, has now become a reality in a biopharmaceutical company in Wuhan. Human serum albumin manufactured in this way is not only safer and more environmentally friendly, but also has the advantages of large-scale production and low cost. It is expected to become an important solution to alleviate the shortage of human serum albumin in my country. At present, the human serum albumin product developed using this technology has completed phase III clinical trials and entered the new drug approval process. The team has built an intelligent factory with an annual output of 1 million injections and is building a large-scale production base with an annual output of 12 million injections. https://finance.eastmoney.com/a/202504063365597167.html
- Source: drugdu
- 64
- April 8, 2025
Firmly oppose! China Chamber of Commerce for Import and Export of Medicines and Health Products issued a statement on the so-called “reciprocal tariffs” imposed by the United States

On April 5, China Chamber of Commerce for Import and Export of Medicines and Health Products issued a statement on the so-called “reciprocal tariffs” imposed by the United States. On April 2, 2025, Eastern Time, the US government announced the imposition of so-called “reciprocal tariffs” on all trading partners, including China. Most medical consumables, dressings, medical equipment and its parts, rehabilitation supplies and other products are affected, especially some products are superimposed on the unreasonable tax increase measures of the US government in the past, and the tariffs have reached extremely high levels. The unilateral trade measures of the US government ignore the rules of the World Trade Organization, which will not only seriously affect the production and operation of global pharmaceutical industry companies including China, but also seriously affect the research and development, production and stability of the global pharmaceutical industry supply chain, and damage the health and well-being ...
- Source: drugdu
- 58
- April 8, 2025
CMEF Guangzhou

Organiser: Reed Sinopharm Exhibitions Time: September 26 – 29, 2025 Address: No. 380, Yuejiang Middle Road, Haizhu District, Guangzhou City Exhibition hall: Canton Fair Complex – Pazhou Hall, Guangzhou Product range: Medical Imaging Zone: Radiology products, ultrasound products, nuclear medicine products, molecular imaging, interventional products, etc. Operating Room Zone: Hybrid operating rooms, integrated operating room solutions, surgical instruments, anesthesia machines, ventilators, patient monitors, operating room engineering, surgical lights, pendant systems, etc. In Vitro Diagnostics Zone: Total laboratory solutions, clinical diagnostic equipment, diagnostic reagents, POCT (Point-of-Care Testing), home diagnostic devices, etc. Rehabilitation & Physiotherapy Zone: Rehabilitation equipment, assistive devices, traditional Chinese medicine treatments, physiotherapy equipment, medical high-frequency devices, etc. Orthopedics Zone: Orthopedic implants (joints, trauma, spine), orthopedic surgical instruments and equipment, bone power tools, and other orthopedic-related products. Medical Informatics Zone: System integrators, mobile healthcare, medical management, quality control, clinical hospital information management systems, IT equipment providers (display, printing, storage), ...
- Source: drugdu
- 55
- April 8, 2025
Yangtze River Pharmaceuticals enters the race for Elamod

Recently, the official website of the National Medical Products Administration (NMPA) showed that Yangtze River Pharmaceutical’s Aguratimod tablets, which were applied for as a generic 4 drug, were officially approved for marketing, becoming the second company in China to have its generic drug approved and pass the consistency evaluation. This progress not only marks a further breakthrough for Yangtze River Pharmaceutical in the field of anti-rheumatic diseases, but also provides more treatment options for domestic patients with rheumatoid arthritis. Eguratimod tablets are a new type of disease-modifying antirheumatic drug (DMARDs) that has both anti-inflammatory and immunomodulatory mechanisms. It can inhibit the production of inflammatory factors such as IL-6 and TNF-α, while delaying bone erosion and promoting bone formation. Clinical data show that it can be effective in 2-4 weeks when used in combination with methotrexate, with a patient remission rate of over 60%, and significantly lower liver toxicity and infection ...
- Source: drugdu
- 72
- April 7, 2025
Liraglutide obtains FDA approval, and global layout leads Chinese pharmaceutical companies to go overseas

On April 3, Jianyou Shares (603707) issued an announcement that the company recently received an approval letter for liraglutide injection, 18 mg/3 mL (6 mg/mL), (ANDA No.: 218115) issued by the US Food and Drug Administration. The drug has a specification of 18mg/3mL (6mg/mL) and can be used as an adjunct to diet and exercise to improve blood sugar control in adults and children aged 10 years and above with type 2 diabetes, while reducing the risk of major adverse cardiovascular events in adult patients with type 2 diabetes with cardiovascular disease. So far, the company has invested approximately RMB 57.37 million in the research and development project of liraglutide injection. The newly approved product will be available in the United States in the near future and is expected to have a positive impact on the company’s operating performance. This event has become an important window for observing its global ...
- Source: drugdu
- 45
- April 7, 2025
The number of measles cases in the United States is more than twice that of the same period last year, and it is still increasing! How is the infection situation in my country?

The measles epidemic in the United States is attracting great attention from the health department. The latest report from the Centers for Disease Control and Prevention (CDC) of the United States stated that as of April 3, the total number of measles cases in the United States has reached 607, more than double the 285 cases in the same period last year. The number of cases increases by more than 100 cases every week. According to the report of the Texas Department of State Health Services on April 4, the total number of measles cases in the state has now reached 481, an increase of 59 cases in three days, an increase of 14%; the number of hospitalizations has increased from 42 to 56. Sapna Singh, chief medical officer of Texas Children’s Hospital, said that judging from the current official reported data, measles cases are far from reaching the goal ...
- Source: drugdu
- 42
- April 7, 2025
The first Chinese PA-targeted anti-influenza drug is approved! The 10 billion influenza market has a new strong player

Masulaxavir Tablets——China’s first independently developed anti-influenza drug targeting PA On March 27, according to the official website of NMPA: Masulaxavir Tablets (trade name: Isuda), a Class 1 innovative drug applied for by Jiangxi Kerui Pharmaceutical Co., Ltd., a subsidiary of Qingfeng Pharmaceutical, was approved for marketing. It is used to treat previously healthy adolescents and adults aged 12 years and above with simple influenza A and B, excluding patients at high risk of influenza-related complications. In recent years, the incidence of influenza has continued to rise internationally , driving a surge in demand for anti-influenza drugs. According to Yaozhi data, the market size of anti-influenza drugs in China will approach 20 billion yuan in 2023. In such a huge market context, the approval of Masulaxavir Tablets is undoubtedly a blockbuster. Masulaxavir tablets are an innovative anti-influenza virus drug jointly developed by Qingfeng Pharmaceutical and Ginkgo Biloba Pharmaceuticals. It is a ...
- Source: drugdu
- 42
- April 7, 2025
【EXPERT Q&A】What qualifications are required for the export of cosmetic raw materials?

Drugdu.com expert’s response: Depending on the target market, exporting cosmetic ingredients requires compliance with China’s export qualifications, import regulations of the target country, and international certification standards. Below are the specific requirements: I. China’s Export Qualification Requirements 1. Enterprise Qualification Registration Customs Registration: Complete the Registration for Foreign Trade Operators and obtain the registration certificate. Business License: The scope of business must include “import/export of goods” or “import/export of technology,” and a copy of the license must be provided. Tax Compliance: Submit the tax registration certificate (if the three certificates have been integrated, it is included in the business license). Foreign Exchange and Tax Rebates: Complete the procedures for opening a foreign exchange account and registering for export tax rebates (if applicable). 2. Product Compliance Documents Material Safety Data Sheet (MSDS): Outline the physical and chemical properties, toxicity, first aid measures, etc., of the ingredients. Component Analysis Report: Issued by a qualified ...
- Source: drugdu
- 55
- April 7, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.